MedTech Europe welcomes ambitious EU Life Sciences Strategy

Posted on 03.07.2025

On 2 July 2025, the European Commission released its much-anticipated Life Sciences Strategy (LSS), setting an ambitious vision to make the EU the world’s most attractive region for life sciences by 2030. MedTech Europe welcomes this comprehensive strategy, which recognises the essential contribution of medical technology alongside pharmaceuticals and biotechnology.

Europe’s medical technology sector is one of its most dynamic and innovative, with over 37,000 companies, 880,000 employees, and 8% of all European patent applications. The sector delivers €11 billion in positive trade balance annually and plays a vital role in strengthening healthcare systems and patient outcomes.

MedTech Europe supports the LSS’s focus on regulatory reform but stresses the urgent need for further simplification—not only within the sector’s framework but also across digital, data, and sustainability regulations. Streamlined, predictable, and innovation-friendly rules are essential to ensure timely patient access and global competitiveness.

We stand ready to contribute to the successful implementation of the LSS, including through the future Coordination Board, and call for bold action to position Europe as the global leader in MedTech innovation.

Read our full statement [here].

For further information, please contact Melanie Wahl, Senior Policy Advisor.